A first-line regimen involving pembrolizumab (Keytruda) and olaparib (Lynparza) significantly reduced the risk of disease ...

Olaparib, an inhibitor of poly (ADP-ribose) polymerase (PARP), has demonstrated promising outcomes in treating HER2-negative early-stage breast cancer with BRCA mutations. However, a comprehensive ...

New Delhi: The Drug Controller General of India (DCGI), Rajeev Raghuvanshi, has directed state authorities to withdraw AstraZeneca’s Olaparib Tablets, 100mg and 150mg, due to potential adverse ...

Sky News presenter Jacquie Beltrao has lived in her stylish home in south-west London for 12 years with her husband Eduardo ...

Sky presenter Jacquie Beltrao opens up about the milestone 60th she wondered if she'd reach, how husband Eduardo has been her ...

Jacquie Beltrao was diagnosed with incurable stage four breast cancer in 2020 but, following chemotherapy and a mastectomy, ...

Final results from the trial showed that olaparib -- a pioneering type of drug called a PARP inhibitor, a cancer drug to target an inherited genetic fault -- can be used successfully to treat ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Niraparib maintenance has a tolerable safety profile in patients with ovarian cancer, with hematologic toxicities being “the primary concern,” according to researchers. They evaluated the safety of ...

The company had received marketing authorisation for Olaparib film-coated tablets 100mg and 150mg (Lynparza) on November 17, 2023, AstraZeneca Pharma India said in a regulatory filing.